CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 176 enrolled
Drug / intervention
BMS747158drug
Likely dose
BMS747158 total dose not to exceed 14 mCi (millicuries) administered as IV bolus injections at rest and during stressAI-extracted
Key inclusion· 3
  • Age 18–75 years, male or non-pregnant female
  • Prior rest/stress SPECT imaging study within 21 days showing reversible ischemia using 99mTc-labeled tracers
  • Female patients must be non-lactating and either post-menopausal (≥12 consecutive months amenorrhea) or surgically sterilized
Key exclusion· 8
  • Presence of conditions that disrupt/increase blood–brain barrier permeability: multiple sclerosis, Alzheimer's disease, Parkinson's disease, acute CNS infection, CNS tumor, CNS autoimmune disease, or CNS inflammatory condition
  • Known hypersensitivity to adenosine, dipyridamole, or aminophylline
  • History of New York Heart Association Class III or IV Congestive Heart Failure
  • Any major surgery within 4 weeks prior to enrollment or planned within 2 weeks following completion of follow-up assessment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00849108
NCT00849108Phase 2Completed

A Phase 2, Open-Label, Randomized Multicenter Study for the Development of One-Day Rest/Stress Cardiac Positron Emission Tomography (PET) Perfusion Imaging Protocols of BMS747158

Lantheus Medical Imaging·interventional·Posted Feb 23, 2009·Updated Oct 14, 2015

In Brief

A Phase 2 clinical trial evaluating BMS747158 for Ischemia. Completed, enrolled 176 participants across 24 sites.

Detailed Summary

The main purpose of this study is to get more information on using BMS747158 (the study drug),a drug with small amounts of radioactivity to allow for heart imaging, during a PET scan which can then be compared to other images such as SPECT. The safety and quality of images will be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 23, 2009
Enrollment StartJan 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.4 years ago

Interventions

BMS747158drug

dosages at rest and at stress were not to exceed a total of 14 mCi. Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period. Cohort 2: Patients to recieve IV bolus injections of BMS747158: For the Pharmacologic (Adenosine) Stress: * Doses at rest were to range between 2.9 and 3.4 mCi. * Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi. For the Exercise Stress: * Doses at rest were to range between 1.7 and 2.0 mCi. * Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.